Results 131 to 140 of about 31,379 (210)

Clonal Hematopoiesis of Indeterminate Potential in Crohn's Disease and Ulcerative Colitis. [PDF]

Inflamm Bowel Dis
Esai Selvan M, Nathan DI, Guisado D, Collatuzzo G, Iruvanti S, Boffetta P, Mascarenhas J, Hoffman R, Cohen LJ, Marcellino BK, Gümüş ZH.   +10 more
europepmc   +1 more source

Pharmacogenetic Testing for DPD Deficiency: Four and a Half Years' Experience in a Large German Laboratory. [PDF]

Dtsch Arztebl Int
Pretzsch T, Schwab M, Blau O, Wörmann B, Stintzing S, Bullinger L, Burmeister T.   +6 more
europepmc   +1 more source

A Review of the Intrinsic Chemical Stability Challenge in Operational Perovskite Photovoltaics. [PDF]

Materials (Basel)
Bì H, Wang Z, Xu Z.
europepmc   +1 more source

Immune checkpoint inhibitors alone or in combination for endometrial mismatch repair-deficient/MSI-high population. [PDF]

ESMO Open
Canario R, Colombo N, Joly F.
europepmc   +1 more source

Journal Staff [PDF]

, 2006

core   +1 more source

Engineering N-acyl-homoserine lactone-based quorum-sensing circuit for dynamic regulatory control in Saccharomyces cerevisiae. [PDF]

Commun Biol
van Aalst ACA, Holtz M, Lyskjær Jensen M, Schröder T, Crocoll C, Poborsky M, Damgaard Jensen E, Krogh Jensen M.   +7 more
europepmc   +1 more source

Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study. [PDF]

Oncologist
Joly F, Lefeuvre-Plesse C, Charton E, Helissey C, Priou F, Stefani L, Simmet V, Bonnet E, Meneveau N, Houede N, Salas S, Bourbouloux E, Nenan S, Rieger I, Descotes JM, Anota A.   +15 more
europepmc   +1 more source

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03. [PDF]

Breast
Trédan O, Loirat D, Chabaud S, Toussaint P, Petit T, Viret F, Levy C, Robert A, Grenier J, Mansi L, Spano JP, Patsouris A, Derbel O, Jouannaud C, Ferrero JM, Frenel JS, Molin Y, Doublet L, Heudel PE, Pierga JY, Garin G, Pérol D, Bachelot T.   +22 more
europepmc   +1 more source

Corporate branding and higher education: a contradiction in terms? [PDF]

, 2013
Parker-Jenkins, M, Spry, LM
core  

Adjuvant treatment algorithm based on recent ESGO/ESTRO/ESP guidelines for early endometrial carcinoma according to prognostic risk groups. [PDF]

J Gynecol Oncol
Baurain JF, Kirkove C, Francois A, Ferron G, Luyckx M.   +4 more
europepmc   +1 more source